Arvinas Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
6.61
-0.2
(-2.94%)
Volume:
1,633,978
52 week range:
5.94 - 37.38
Market Cap:
482.473M
Company Description:
Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)